cm-101
Primary Sclerosing Cholangitis
ChemomAb Ltd.Phase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
22 Active assets in the Primary Sclerosing Cholangitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vancomycin Tampere University Hospital | Phase 4 | BB |
URSODEOXYCHOLIC ACID Assistance Publique - Hôpitaux de Paris | Phase 3 | BB |
Elafibranor Ipsen | Phase 3 | B |
Aldafermin NGM Biopharmaceuticals, Inc | Phase 2/3 | B |
htd1801 HighTide Biopharma Pty Ltd | Phase 2 | B |
View all 50 →
Same molecule, other indications
cm-101 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →